Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Bioptimus logo — We build foundation models that will transform biology.

Bioptimus

We build foundation models that will transform biology.

Founded 2024 France France 44 employees Series A Total: $76.00M Biotechnology, Pharmaceutical

General Information

Company Name Bioptimus
Founded Year 2024
Location France France
Founders / Decision Makers
Team member
Employees 44
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, SaaS, API
Revenue Model Subscription, Usage Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Bioptimus. To contact Bioptimus, visit bioptimus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bioptimus compare?

A PDF of Bioptimus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bioptimus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

In The News Oct 01, 2026

Featured on Tech: Mistral and Black Forest Labs backer Headline closes $400M European fund

Get alerts when Bioptimus shows new signals

About Bioptimus

Bioptimus is a forward-thinking company established in 2024 in France, specializing in the Biotechnology and Pharmaceutical industries. The startup’s mission is encapsulated in its slogan: "We build foundation models that will transform biology."

Bioptimus leverages cutting-edge technology to convert multiscale data into actionable insights, positioning itself as a leader in fostering breakthrough discoveries. As part of its strategy, the company is developing foundation models aimed at revolutionizing biological sciences.

Most recently, Bioptimus secured a substantial $41.00M Series A investment on 01 January 2025. This round of funding was supported by an impressive lineup of investors, including Cathay Innovation, Bpifrance, Sofinnova Investments, Andera Partner, Boom Capital Ventures, Hitachi Ventures, Emmanuel Cassimatis, and Thomas Wolf. Bioptimus's promising technology and strong investor backing signal significant growth potential in the biotech sector.

Business keywords: foundation models, multiscale data, biological data integration, AI in biology, biological processes, computational biology, biological discoveries, data-driven biology, universal AI, advanced computing power, molecular biology, organismal biology, data representation

Services & Products

Biological Data Generation
Multimodal Foundation Model Development
Drug Response Prediction
Biomarker and Target Discovery
Spatial Transcriptomics Integration

Target Customers

Pharmaceutical Companies Biotech Researchers Clinical Trial Organizations Academic Institutions Healthcare Providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $41.00M 8
Cathay Innovation Bpifrance Sofinnova Investments
Cathay Innovation, Bpifrance +6
01 Jan 2025
Seed $35.00M 8
Cathay Innovation Bpifrance Sofinnova Partners
Cathay Innovation, Bpifrance +6
01 Feb 2024

Latest News

View All
Mistral and Black Forest Labs backer Headline closes $400M European fund — Tech
Mistral and Black Forest Labs backer Headline closes $400M European fund
Tech Oct 01, 2026
France’s startup scene is falling behind the US and Europe, and AI is both the cause and the cure — Thenextweb
France’s startup scene is falling behind the US and Europe, and AI is both the cause and the cure
Thenextweb May 27, 2026
10 French startups to keep an eye on in 2026 and beyond! — Eu-startups
10 French startups to keep an eye on in 2026 and beyond!
Eu-startups Jan 15, 2026
OpenAI to Acquire Poland’s Neptune, Integrating Advanced Metrics Dashboards With AI — Coincentral.com
OpenAI to Acquire Poland’s Neptune, Integrating Advanced Metrics Dashboards With AI
Coincentral.com Dec 04, 2025
An LLM for biotech: French startup Bioptimus raises $35m seed — Sifted
An LLM for biotech: French startup Bioptimus raises $35m seed
Sifted Nov 23, 2025
Bioptimus: AI-Powered Bioscience Startup Raises $35 Million — Businessinsider.com
Bioptimus: AI-Powered Bioscience Startup Raises $35 Million
Businessinsider.com Nov 23, 2025

Bioptimus Alternatives & Competitors

View All Alternatives
Bioptimus vs
leon-nanodrugs
leon-nanodrugs Germany

THE FUTURE OF NANOPARTICLE MANUFACTURING

Series B
20 employees
Biotechnology, Health Care
Bioptimus vs
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. United States

Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS...

Series C
128 employees
Biotechnology, Health and Wellness
Bioptimus vs
Code Ocean
Code Ocean United States

Making science move faster.

Series B
37 employees
Biotechnology, IT
View all alternatives

FAQ About Bioptimus

We build foundation models that will transform biology.
Bioptimus was founded in 2024.
Bioptimus is headquartered in France.
Bioptimus operates in Biotechnology and Pharmaceutical. Its work centres on foundation models, multiscale data, biological data integration and AI in biology. Its customers include Pharmaceutical Companies, Biotech Researchers and Clinical Trial Organizations.
Bioptimus has a B2B, SaaS and API business model. Its revenue comes from Subscription, Usage Based and Licensing.
Bioptimus has approximately 44 employees.
Bioptimus has completed 2 funding rounds, raising a total of $76.00M. The latest funding stage is Series A.
Bioptimus offers: Biological Data Generation, Multimodal Foundation Model Development, Drug Response Prediction, Biomarker and Target Discovery, Spatial Transcriptomics Integration.
Top alternatives and competitors to Bioptimus include leon-nanodrugs, Aspen Neuroscience, Inc., Code Ocean, Phastar, Cellarity. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bioptimus and leon-nanodrugs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bioptimus, https://bouncewatch.com/company/bioptimus, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes